{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:24:45Z","timestamp":1790807085934,"version":"4.1.0"},"reference-count":26,"publisher":"The Endocrine Society","issue":"1","license":[{"start":{"date-parts":[[2022,9,3]],"date-time":"2022-09-03T00:00:00Z","timestamp":1662163200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,12,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Context<\/jats:title>\n                  <jats:p>Dysbetalipoproteinemia (DBL) is a disorder in which remnant lipoproteins accumulate in the plasma due to a genetic apolipoprotein E dysfunction in conjunction with the presence of secondary metabolic factors. An increased risk of both coronary and peripheral vascular disease (PVD) has been observed in these patients in retrospective studies.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>The primary objective was to compare the incidence of atherosclerotic cardiovascular disease (ASCVD) and PVD in a cohort of patients with DBL compared with normolipidemic controls. As a secondary objective, the incidence of ASCVD and PVD was compared between patients with DBL and patients with familial hypercholesterolemia (FH).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A total of 221 patients with DBL, 725 patients with FH, and 1481 normolipidemic controls were included in the study. The data were obtained by review of medical records.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In patients with DBL, there was an overall excess risk of PVD (hazard ratio [HR] 13.58, 95% CI 4.76-38.75) and ASCVD (HR 3.55, 95% CI 2.17-5.83) (P &amp;lt; .0001) when compared with normolipidemic controls. When compared with patients with FH, an increased risk of PVD (HR 3.89, 95% CI 1.20-12.55, P = .02) was observed in patients with DBL.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>We demonstrated that the risks of ASCVD and PVD in DBL are &amp;gt;3-fold and &amp;gt;13-fold higher, respectively, than normolipidemic controls. Furthermore, the risk of PVD is \u223c4-fold higher in DBL than in FH. Adequate screening of DBL is imperative to improve the clinical care of these patients by preventing the development of ASCVD.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/clinem\/dgac503","type":"journal-article","created":{"date-parts":[[2022,9,3]],"date-time":"2022-09-03T12:09:09Z","timestamp":1662206949000},"page":"184-190","source":"Crossref","is-referenced-by-count":26,"title":["Dysbetalipoproteinemia Is Associated With Increased Risk of Coronary and Peripheral Vascular Disease"],"prefix":"10.1210","volume":"108","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7555-1275","authenticated-orcid":false,"given":"Martine","family":"Paquette","sequence":"first","affiliation":[{"name":"Lipids, Nutrition, and Cardiovascular Prevention Clinic of the Montreal Clinical Research Institute , Montreal, QC , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Bernard","sequence":"additional","affiliation":[{"name":"Lipids, Nutrition, and Cardiovascular Prevention Clinic of the Montreal Clinical Research Institute , Montreal, QC , Canada"},{"name":"Department of Medicine, Division of Endocrinology, Universit\u00e9 de Montreal , Montreal, QC , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9534-1657","authenticated-orcid":false,"given":"Alexis","family":"Baass","sequence":"additional","affiliation":[{"name":"Lipids, Nutrition, and Cardiovascular Prevention Clinic of the Montreal Clinical Research Institute , Montreal, QC , Canada"},{"name":"Department of Medicine, Divisions of Experimental Medicine and Medical Biochemistry, McGill University , Montreal, QC , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2022,9,3]]},"reference":[{"key":"2022121716480114200_dgac503-B1","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.atherosclerosis.2021.04.001","article-title":"Adiposity and the development of dyslipidemia in APOE \u03b52 homozygous subjects: a longitudinal analysis in two population-based cohorts","volume":"325","author":"Heidemann","year":"2021","journal-title":"Atherosclerosis"},{"issue":"2","key":"2022121716480114200_dgac503-B2","doi-asserted-by":"crossref","first-page":"150","DOI":"10.7326\/0003-4819-82-2-150","article-title":"Type III hyperlipoproteinemia: an analysis of two contemporary definitions","volume":"82","author":"Fredrickson","year":"1975","journal-title":"Ann Intern Med"},{"issue":"1","key":"2022121716480114200_dgac503-B3","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1194\/jlr.D200013-JLR200","article-title":"Non-denaturing polyacrylamide gradient gel electrophoresis for the diagnosis of dysbetalipoproteinaemia","volume":"44","author":"Blom","year":"2003","journal-title":"J Lipid Res"},{"issue":"4","key":"2022121716480114200_dgac503-B4","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.jacl.2020.06.004","article-title":"A simplified diagnosis algorithm for dysbetalipoproteinemia","volume":"14","author":"Paquette","year":"2020","journal-title":"J Clin Lipidol"},{"issue":"4","key":"2022121716480114200_dgac503-B5","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/MOL.0000000000000831","article-title":"Diagnosis of remnant hyperlipidaemia","volume":"33","author":"Paquette","year":"2022","journal-title":"Curr Opin Lipidol"},{"issue":"5","key":"2022121716480114200_dgac503-B6","doi-asserted-by":"crossref","first-page":"993","DOI":"10.5114\/aoms.2019.86972","article-title":"Modern prevalence of dysbetalipoproteinemia (Fredrickson-Levy-Lees type III hyperlipoproteinemia)","volume":"16","author":"Pallazola","year":"2019","journal-title":"Arch Med Sci"},{"issue":"1","key":"2022121716480114200_dgac503-B7","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jacl.2019.12.006","article-title":"Triglycerides, hypertension, and smoking predict cardiovascular disease in dysbetalipoproteinemia","volume":"14","author":"Paquette","year":"2020","journal-title":"J Clin Lipidol"},{"issue":"2","key":"2022121716480114200_dgac503-B8","doi-asserted-by":"crossref","first-page":"158","DOI":"10.7326\/0003-4819-82-2-158","article-title":"The biochemical, clinical, and genetic features of type III hyperlipoproteinemia","volume":"82","author":"Morganroth","year":"1975","journal-title":"Ann Intern Med"},{"issue":"5","key":"2022121716480114200_dgac503-B9","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1007\/BF00186624","article-title":"Clinical features of type III hyperlipoproteinemia: analysis of 64 patients","volume":"71","author":"Feussner","year":"1993","journal-title":"Clin Investig"},{"issue":"1","key":"2022121716480114200_dgac503-B10","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.atherosclerosis.2015.02.046","article-title":"Vascular risk factors, vascular disease, lipids and lipid targets in patients with familial dysbetalipoproteinemia: a European cross-sectional study","volume":"240","author":"Koopal","year":"2015","journal-title":"Atherosclerosis"},{"issue":"1","key":"2022121716480114200_dgac503-B11","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jacl.2010.11.004","article-title":"Etiology and risk of lactescent plasma and severe hypertriglyceridemia","volume":"5","author":"Tremblay","year":"2011","journal-title":"J Clin Lipidol"},{"issue":"2","key":"2022121716480114200_dgac503-B12","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1161\/hq0202.102919","article-title":"Expression of type III hyperlipoproteinemia in apolipoprotein E2 (Arg158 \u2192 Cys) homozygotes is associated with hyperinsulinemia","volume":"22","author":"de Beer","year":"2002","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"11","key":"2022121716480114200_dgac503-B13","first-page":"892","article-title":"Dysbetalipoproteinaemia\u2013clinical and pathophysiological features","volume":"92","author":"Blom","year":"2002","journal-title":"S Afr Med J"},{"issue":"2","key":"2022121716480114200_dgac503-B14","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1210\/clinem\/dgab648","article-title":"Dysbetalipoproteinemia: differentiating multifactorial remnant cholesterol disease from genetic ApoE deficiency","volume":"107","author":"Paquette","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"2022121716480114200_dgac503-B15","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1161\/ATVBAHA.121.316106","article-title":"Familial hypercholesterolemia-risk-score: a new score predicting cardiovascular events and cardiovascular mortality in familial hypercholesterolemia","volume":"41","author":"Paquette","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"9","key":"2022121716480114200_dgac503-B16","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1007\/s11883-014-0440-2","article-title":"Hyperlipoproteinemia type 3: the forgotten phenotype","volume":"16","author":"Hopkins","year":"2014","journal-title":"Curr Atheroscler Rep"},{"issue":"2","key":"2022121716480114200_dgac503-B17","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1373\/clinchem.2018.298026","article-title":"Type III hyperlipoproteinemia: the forgotten, disregarded, neglected, overlooked, ignored but highly atherogenic, and highly treatable dyslipoproteinemia","volume":"65","author":"Sniderman","year":"2019","journal-title":"Clin Chem"},{"key":"2022121716480114200_dgac503-B18","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.atherosclerosis.2021.06.006","article-title":"Paternal inheritance predicts earlier cardiovascular event onset in patients with familial hypercholesterolemia","volume":"329","author":"Paquette","year":"2021","journal-title":"Atherosclerosis"},{"issue":"34","key":"2022121716480114200_dgac503-B19","doi-asserted-by":"crossref","first-page":"3258","DOI":"10.1093\/eurheartj\/ehab705","article-title":"Elevated remnant cholesterol increases the risk of peripheral artery disease, myocardial infarction, and ischaemic stroke: a cohort-based study","volume":"43","author":"Wadstr\u00f6m","year":"2022","journal-title":"Eur Heart J"},{"issue":"21","key":"2022121716480114200_dgac503-B20","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1161\/CIRCULATIONAHA.118.035432","article-title":"Lipoprotein particle profiles, standard lipids, and peripheral artery disease incidence","volume":"138","author":"Aday","year":"2018","journal-title":"Circulation"},{"issue":"17","key":"2022121716480114200_dgac503-B21","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1016\/j.jacc.2020.02.059","article-title":"Triglyceride-rich lipoprotein cholesterol, small dense LDL cholesterol, and incident cardiovascular disease","volume":"75","author":"Duran","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"2022121716480114200_dgac503-B22","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/nrcardio.2017.31","article-title":"Hypertriglyceridaemia and risk of coronary artery disease","volume":"14","author":"Reiner","year":"2017","journal-title":"Nat Rev Cardiol"},{"issue":"4","key":"2022121716480114200_dgac503-B23","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1161\/CIRCRESAHA.115.306249","article-title":"Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease: new insights from epidemiology, genetics, and biology","volume":"118","author":"Nordestgaard","year":"2016","journal-title":"Circ Res"},{"issue":"12","key":"2022121716480114200_dgac503-B24","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1161\/CIRCULATIONAHA.113.003008","article-title":"Elevated remnant cholesterol causes both low-grade inflammation and ischemic heart disease, whereas elevated low-density lipoprotein cholesterol causes ischemic heart disease without inflammation","volume":"128","author":"Varbo","year":"2013","journal-title":"Circulation"},{"issue":"1","key":"2022121716480114200_dgac503-B25","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"issue":"3","key":"2022121716480114200_dgac503-B26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0265838","article-title":"Effect of PCSK9 inhibition with evolocumab on lipoprotein subfractions in familial dysbetalipoproteinemia (type III hyperlipidemia)","volume":"17","author":"Waldmann","year":"2022","journal-title":"PLoS One"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgac503\/46342467\/dgac503.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/108\/1\/184\/48076725\/dgac503.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/108\/1\/184\/48076725\/dgac503.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T16:48:21Z","timestamp":1671295701000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/108\/1\/184\/6691221"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,3]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,9,3]]},"published-print":{"date-parts":[[2022,12,17]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgac503","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,1,1]]},"published":{"date-parts":[[2022,9,3]]}}}